Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells

References

• Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest. 2017;97:669–697. doi:10.1038/labinvest.2017.25
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi:10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A. 2009;106:16157–16162. doi:10.1073/pnas.0908201106
   PubMed Web of Science ®Google Scholar
• Marelli UK, Rechenmacher F, Sobahi TR, Mas-Moruno C, Kessler H. Tumor Targeting via Integrin Ligands. Front Oncol. 2013;3:222. doi:10.3389/fonc.2013.00222
   PubMedGoogle Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16:510–520. doi:10.1016/j.ccr.2009.10.013
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328:1031–1035. doi:10.1126/science.1183057
   PubMed Web of Science ®Google Scholar
• Ding N, Zou Z, Sha H, et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun. 2019;10:1336. doi:10.1038/s41467-019-09296-6
   PubMed Web of Science ®Google Scholar
• Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43:1129–1143. doi:10.1016/j.molimm.2005.07.034
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–847. doi:10.1016/j.drudis.2015.02.008
   PubMed Web of Science ®Google Scholar
• Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015;64(6):677–688. doi:10.1007/s00262-015-1671-y
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. doi:10.1126/scitranslmed.3003689
   PubMed Web of Science ®Google Scholar
• Junttila TT, Li J, Johnston J, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014;74(19):5561–5571. doi:10.1158/0008-5472.CAN-13-3622-T
   PubMed Web of Science ®Google Scholar
• Chang CH, Wang Y, Li R, et al. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. Cancer Res. 2017;77:5384–5394. doi:10.1158/0008-5472.CAN-16-3431
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi:10.1126/science.aaa4967
   PubMed Web of Science ®Google Scholar
• Hiwarkar P, Qasim W, Ricciardelli I, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015;126(26):2882–2891. doi:10.1182/blood-2015-06-654780
   PubMed Web of Science ®Google Scholar
• Berglund S, Gertow J, Magalhaes I, Mattsson J, Uhlin M. Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential. J Immunother. 2013;36(8):432–441. doi:10.1097/CJI.0b013e3182a802f6
   PubMed Web of Science ®Google Scholar
• Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharmacol Ther. 2018;182:161–175. doi:10.1016/j.pharmthera.2017.08.005
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Bacac M, Fauti T, Sam J, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the Treatment of Solid Tumors. Clin Cancer Res. 2016;22(13):3286–3297. doi:10.1158/1078-0432.CCR-15-1696
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Sano Y, Komatsu SI, et al. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017:9. doi:10.1126/scitranslmed.aal4291.
   Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–2199. doi:10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–1469. doi:10.1126/science.aaf1490
   PubMed Web of Science ®Google Scholar
• Balko JM, Sosman JA. A critical need for better cancer immunotherapy models: are organotypic tumor spheroid cultures the answer. Cancer Discov. 2018;8:143–145. doi:10.1158/2159-8290.CD-17-1356
   PubMed Web of Science ®Google Scholar
• Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216–233. doi:10.1158/2159-8290.CD-17-0915
   PubMed Web of Science ®Google Scholar
• Fadeev R, Chekanov A, Solovieva M, et al. Improved anticancer effect of recombinant protein izTRAIL Combined with Sorafenib and Peptide iRGD. Int J Mol Sci. 2019:20. doi:10.3390/ijms20030525.
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhu M, Meng F, et al. Evaluation of PD-1 blockade using a multicellular tumor spheroid model. Am J Transl Res. 2019;11:7471–7478. doi:10.1126/science.aaf1490
   PubMed Web of Science ®Google Scholar